2.

H RNMRD measurements
Solution preparation:
The exact ligand concentrations were determined by adding an excess of lanthanide solution to the ligand solution and titrating the metal excess with standardised Na2H2EDTA in urotropine buffer (pH 5.6 -5.8) in the presence of Xylenol Orange as an indicator. The concentrations of the metal solutions were determined similarly by complexometric titrations.
The complexes were prepared by mixing 1 eq. of L, with 1 eq. of Gd 3+ , and the pH was adjusted to 7.4 either with a buffered solution or by adding KOH or HCl to the solution. The absence of free Gd 3+ was checked by the Xylenol orange test.
The concentrations of Gd
3+
-containing solutions were also checked by ICP-MS and BMS measurements when possible. Zn 2+ concentrations were also checked by ICP-MS.
HSA was used in its fatty-acid free form.
Relaxometric measurements:
Proton NMRD profiles were performed on a Bruker WP80 NMR electromagnet adapted to variable field measurements (20-80 MHz) and controlled by a SMARTracer PC-NMR console, or on a minispec Bruker "mqvar" (20, 30, 40, 60 MHz). The temperature was monitored by a VTC91 temperature control unit and maintained by a gas flow. The temperature was determined by previous calibration with a Pt resistance temperature probe. Relaxivities at 100 MHz and 400 MHz were measured on a Bruker Advance 100 and 400, respectively. The longitudinal relaxation rates (1/T1) were determined in water.
FFC-MRI measurements and analysis
The FFC-MRI hardware was implemented by means of an additional B0 insert coil (Resonance Research Inc., USA) synchronized with a clinical MRI system (Skyra, Siemens Healthineers, Germany) with a main magnetic field strength B0 of 2.89 T Table S1 . The increase of median R1/B0
values in Table 1 
